哌马色林的合成研究进展

Advances in synthesis of pimavanserin

哌马色林(匹莫范色林,pimavanserin,Nuplazid)是选择性靶向5-HT2A受体药,由美国Acadia Pharmaceuticals公司研制,2016年4月29日获FDA批准用于治疗帕金森病(PD)患者所经历幻觉和妄想等精神症状。本文综述了近年来文献报道的该药合成方法,并对其优缺点进行评述。

Pimavanserin（Nuplazid） is a drug of selective targeting 5-HT2 Areceptor,developed by Acadia Pharmaceuticals.In April 29,2016,it was approved by FDA for the treatment of Parkinson′s disease（PD）patients experiencing mental symptoms such as hallucinations and delusions. In this paper,we summarize the synthetic methods of pimavanserin published in literature in recent years and their advantages and disadvantages.